Core Viewpoint - Tianyuan Co., Ltd. announced the suspension of its subsidiary, Mabi Wuqiong Mining Co., Ltd.'s phosphorus chemical plant on December 19, 2023, and plans to transfer its 25,000 tons/year yellow phosphorus production capacity at a base price of 24.79 million yuan through a public listing [1] Group 1 - The yellow phosphorus production capacity of 25,000 tons/year will be publicly listed for transfer at a base price of 24.79 million yuan [1] - Sichuan Hebang Biotechnology Co., Ltd. was determined as the buyer through dynamic bidding at the Southwest United Property Rights Exchange [1] - The transaction contract was signed on November 25, 2025, with a total transaction amount of 185.29 million yuan (including tax) [1]

（文章来源：每日经济新闻） 每经AI快讯，11月26日，天原股份(002386.SZ)公告称，公司以转让底价2479万元，通过在西南联合产 权交易所公开挂牌的方式，对2.5万吨/年黄磷产能指标进行转让，最终确定四川和邦生物科技股份有限 公司为受让方，成交金额为18529万元（含税）。但该交易还需取得马边县对无穷矿业黄磷产能退出的 公示，才能完成交割；若不能取得，交易合同解除，无穷矿业需全额无息退还交易价款。 ...

天原集团公告称，下属子公司无穷矿业磷化工厂于2023年12月19日停产。为盘活闲置无形资产，公司对 2.5万吨/年黄磷产能指标公开挂牌转让。最终确定和邦生物为受让方，2025年11月25日无穷矿业与其签 订《产权交易合同》，成交金额1.85亿元（含税），和邦生物将在合同生效5个工作日内付款。不过， 转让还需取得马边县对无穷矿业黄磷产能退出公示才能完成交割，存在不确定性。 ...

Core Viewpoint - The stock of Hebang Biotechnology has shown fluctuations with a recent increase of 2.37%, while the company faces a decline in revenue and profit year-on-year [1][2]. Financial Performance - As of September 30, 2025, Hebang Biotechnology reported a revenue of 5.927 billion yuan, a decrease of 13.02% year-on-year, and a net profit attributable to shareholders of 93.11 million yuan, down 57.93% year-on-year [2]. - The company has cumulatively distributed 1.205 billion yuan in dividends since its A-share listing, with 553 million yuan distributed over the past three years [3]. Stock Market Activity - On November 25, the stock price reached 2.16 yuan per share, with a trading volume of 289 million yuan and a turnover rate of 1.54%, resulting in a total market capitalization of 19.076 billion yuan [1]. - The stock has increased by 5.88% year-to-date, but has seen a decline of 8.09% over the last five trading days [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 1.99% to 196,500, with an average of 44,939 circulating shares per person, an increase of 2.03% [2]. - Notable institutional shareholders include Penghua CSI Sub-Industry Chemical Theme ETF and Southern CSI 500 ETF, with significant holdings [3].

Core Viewpoint - The stock of Hebang Biotechnology has experienced fluctuations, with a recent decline of 2.35% and a total market capitalization of 18.369 billion yuan, indicating potential volatility in the company's stock performance [1]. Financial Performance - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.927 billion yuan, representing a year-on-year decrease of 13.02%. The net profit attributable to shareholders was 931.085 million yuan, down 57.93% compared to the previous year [2]. - The company's stock price has increased by 1.96% year-to-date, but it has seen a significant decline of 14.75% over the last five trading days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period. The average number of circulating shares per shareholder increased by 2.03% to 44,939 shares [2]. - The company has distributed a total of 1.205 billion yuan in dividends since its A-share listing, with 553 million yuan distributed over the last three years [3]. Major Shareholders - The fourth largest circulating shareholder is Penghua CSI Sub-Industry Chemical Theme ETF Link A, holding 92.788 million shares as a new shareholder. The fifth largest is Southern CSI 500 ETF, holding 90.090 million shares, which has decreased by 2.1844 million shares from the previous period [3]. - Hong Kong Central Clearing Limited is the sixth largest circulating shareholder, holding 89.2826 million shares, which has increased by 1.60908 million shares compared to the previous period [3].

证券日报网讯和邦生物（603077）11月21日在互动平台回答投资者提问时表示，公司目前在国内拥有两 座磷矿，分别是马边烟峰磷矿和汉源刘家山磷矿，储量分别为3，174.10万吨和5，917.80万吨。 ...

Market Overview - The agricultural chemical sector experienced a decline of 5.39% on November 21, with Chengxing Co. leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Individual Stock Performance - Chengxing Co. (600078) closed at 11.42, down 10.01% with a trading volume of 815,900 shares [1] - Lianhua Technology (002250) closed at 11.84, down 9.96% with a trading volume of 846,200 shares [1] - Bluefeng Biochemical (002513) closed at 8.05, down 9.96% with a trading volume of 438,000 shares [1] - Liuguo Chemical (600470) closed at 6.09, down 9.78% with a trading volume of 362,100 shares [1] - Chuanjinno (300505) closed at 21.57, down 8.33% with a trading volume of 246,600 shares [1] - Hebang Bio (603077) closed at 2.13, down 7.79% with a trading volume of 3,585,900 shares [1] - Chuanheng Co. (002895) closed at 34.45, down 7.64% with a trading volume of 216,400 shares [1] - Hongda Co. (600331) closed at 11.05, down 7.61% with a trading volume of 1,041,300 shares [1] - Yantu Holdings (002539) closed at 11.03, down 7.47% with a trading volume of 475,800 shares [1] - Salt Lake Co. (000792) closed at 26.04, down 7.20% with a trading volume of 2,051,800 shares [1] Capital Flow Analysis - The agricultural chemical sector saw a net outflow of 1.435 billion yuan from institutional investors, while retail investors had a net inflow of 1.383 billion yuan [1] - The table of capital flow for individual stocks indicates varying levels of net inflow and outflow among different companies [2] Individual Stock Capital Flow - Hongda Co. (600331) had a net inflow of 56.76 million yuan from institutional investors, but a net outflow from retail investors [2] - Guangxin Co. (603599) saw a net inflow of 27.20 million yuan from institutional investors, with a net outflow from retail investors [2] - Zhongqi Co. (300575) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow from retail investors [2] - Andamite A (000553) experienced a net inflow of 15.01 million yuan from institutional investors, but a significant net outflow from retail investors [2] - Sichuan Meifeng (000731) had a net inflow of 13.36 million yuan from institutional investors, with a net outflow from retail investors [2]

Group 1 - The chemical sector experienced a decline on November 21, with the Chemical ETF (516020) dropping over 4% at one point and closing down 2.84% [1][2] - Key stocks in the sector, such as Enjie Co., Ltd. and Tianqi Lithium, saw significant losses, with Enjie hitting the daily limit down and Tianqi falling over 8% [1][2] - The Chemical ETF has shown a year-to-date increase of 30.5%, outperforming major indices like the Shanghai Composite Index (17.28%) and the CSI 300 Index (16.01%) [1][3] Group 2 - The chemical industry has faced a continuous decline in product prices for four years, but recent policies aimed at reducing competition may signal a turning point [3][4] - The current price-to-book ratio of the Chemical ETF is 2.37, indicating a relatively low valuation compared to the past decade [4] - Analysts suggest that the industry may see improved supply-demand dynamics and profitability due to the "anti-involution" policies, with a focus on sectors like pesticides and organic silicon [5][6] Group 3 - The Chemical ETF (516020) tracks the CSI Sub-Industry Chemical Index, covering various segments of the chemical industry, with nearly 50% of its holdings in large-cap stocks [5][6] - Investors are encouraged to consider the Chemical ETF as a more efficient way to gain exposure to the chemical sector [5][6]

Group 1 - On November 20, Hebang Biotechnology experienced a decline of 0.86% with a transaction volume of 587 million yuan, and the net financing buy was -4.80 million yuan [1] - As of November 20, the total margin balance for Hebang Biotechnology was 596 million yuan, with the financing balance accounting for 2.88% of the circulating market value, indicating a high level compared to the past year [1] - The company repaid 586,500 shares of margin on November 20, while 847,300 shares were sold short, resulting in a short selling amount of 1.96 million yuan [1] Group 2 - As of September 30, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99%, while the average circulating shares per person increased by 2.03% to 44,939 shares [2] - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.93 billion yuan, a year-on-year decrease of 13.02%, and a net profit attributable to shareholders of 93.11 million yuan, down 57.93% year-on-year [2] Group 3 - Since its A-share listing, Hebang Biotechnology has distributed a total of 1.205 billion yuan in dividends, with 553 million yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders included new entrants such as Penghua CSI Sub-Segment Chemical Industry Theme ETF and Everbright Prudential Credit Bond A, indicating changes in institutional holdings [3]

截至9月30日，和邦生物股东户数19.65万，较上期减少1.99%；人均流通股44939股，较上期增加 2.03%。2025年1月-9月，和邦生物实现营业收入59.27亿元，同比减少13.02%；归母净利润9310.85万 元，同比减少57.93%。 分红方面，和邦生物A股上市后累计派现12.05亿元。近三年，累计派现5.53亿元。 机构持仓方面，截止2025年9月30日，和邦生物十大流通股东中，鹏华中证细分化工产业主题ETF联接A （014942）位居第四大流通股东，持股9278.78万股，为新进股东。南方中证500ETF（510500）位居第 五大流通股东，持股9008.99万股，相比上期减少218.44万股。香港中央结算有限公司位居第六大流通股 东，持股8928.26万股，相比上期增加1609.08万股。光大保德信信用添益债券A类（360013）位居第九 大流通股东，持股3300.96万股，为新进股东。中欧红利优享灵活配置混合A（004814）位居第十大流通 股东，持股2459.99万股，为新进股东。 责任编辑：小浪快报 和邦生物今年以来股价涨16.67%，近5个交易日跌1.24%，近20日涨12.26 ...